A National Survey Investigating UK Prescribers' Opinions on Chemotherapy Dosing and 'Dose-Banding'

Clinical Oncology

Volumn 21, Issue 4, 2009, Pages 320-328

  Kaestner, S A ^a   Sewell, G J ^b  

^a PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; dose; dose banding; prescribers; survey; UK

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; DOSE BANDING; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEALTH SURVEY; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; UNITED KINGDOM; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DATABASES AS TOPIC; FOCUS GROUPS; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; QUALITATIVE RESEARCH; QUESTIONNAIRES;

EID: 62949128883     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.12.004     Document Type: Article

References (30)

1. Anon. Development of a dose-banding system. Pharm J 256 (1996) 297
2. Baker J.P., and Jones S.E. Rationalisation of chemotherapy services in the University Hospital Birmingham NHS Trust. J Oncol Pharm Pract 4 (1998) 10-14
3. Plumridge R., and Sewell G.J. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health-Syst Pharm 58 (2001) 1760-1764
4. Kaestner S., and Sewell G. A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'. J Oncol Pharm Pract 13 (2007) 119-126
5. Krämer I. Viability of microorganisms in novel antineoplastic and antiviral drug solutions. J Oncol Pharm Pract 4 (1998) 32-37
6. Paris I., Paci A., Rey J.B., and Bourget P. Microbial growth tests in anti-neoplastic injectable solutions. J Oncol Pharm Pract 11 (2005) 7-12
7. Holmes C.J., Kubey W.Y., and Love D.I. Viability of microorganisms in fluorouracil and cisplatin small-volume injections. Am J Hosp Pharm 45 (1988) 1089-1091
8. So J. Improving the lives of patients with cancer. Pharm Manage 18 (2002) 27-29
9. Tran M. The impact of introducing pre-printed chemotherapy medication charts to a day chemotherapy unit. J Oncol Pharm Pract 6 (2000) 64-69
10. Kaestner S., and Sewell G. Pharmacoeconomic aspects of dose-banding. Hosp Pharm Eur 26 (2006) 33-34
11. Kaestner S., Walker V., Perren T., and Sewell G. Pharmacokinetic assessment of "dose-banded" cancer chemotherapy. Pharmacotherapy 25 (2005) 1545 (abstract)
12. National Cancer Research Network, Available from: http://www.ncrn.org.uk/ (accessed November 2008).
13. Department of Health. The NHS cancer plan (2000), Stationery Office
14. MacLean F., MacIntyre J., McDade J., and Moyes D. Dose-banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J 270 (2003) 691-693
15. Lowe D. Planning for medical research. A practical guide to research methods (1993), Astraglobe, Congleton
16. Differentiating audit, service evaluation and research (July 2006), COREC ethics consultation E-group, London. Available from: www.corec.org.uk/applicants/help/docs/Is_and_As_Differentiating_Research .pdf (accessed November 2006)
17. Directory of cancer care (2006), CMA Medical Data, Loughborough
18. NHS in England. Strategic health authorities, Available from: http://www.nhs.uk/England/AuthoritiesTrusts/Sha/Default.aspx (accessed December 2006).
19. Kaestner S., and Sewell G. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol) 19 (2007) 23-37
20. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
21. Kaestner S., and Sewell G. Dose-banding of carboplatin: rationale and proposed banding scheme. J Oncol Pharm Pract 13 (2007) 109-117
22. Astier A. The stability of anticancer drugs. Eur J Oncol Pharm 1 (2007) 21-23
23. Streiff M.B., Dundes L., and Spivak J.L. A mail survey of United States hematologists and oncologists: a comparison of business reply versus stamped return envelopes. J Clin Epidemiol 54 (2001) 430-432
24. Jyothirmayi R., and Coltart S. An audit of the indications for and techniques of palliative splenic radiotherapy in the UK. Clin Oncol (R Coll Radiol) 17 (2005) 192-194
25. Young J. Mail surveys of general practice physicians: response rates and non-response bias. Swiss Med Wkly 135 (2005) 187-188
26. Asch D., Jedrziewski M., and Christakis N. Response rates to mail surveys published in medical journals. J Clin Epidemiol 50 (1997) 1129-1136
27. Bergk V., Gasse C., Schnell R., and Haefeli W. Mail surveys: obsolescent model or valuable instrument in general practice research?. Swiss Med Wkly 135 (2005) 189-191
28. O'Cathain A., Murphy E., and Nicholl J. Why, and how, mixed methods research is undertaken in health services research in England: a mixed methods study. BMC Health Serv Res 7 (2007) 85
29. Sandelowski M. Sample size in qualitative research. Res Nurs Health 18 (1995) 179-183
30. Benstead K. What is valuable for specialist registrars to learn in order to become good consultant clinical oncologists?. Clin Oncol (R Coll Radiol) 18 (2006) 549-554